Source: ChildrensHealthDefense.org
The results from the first immunization campaign for nirsevimab, the monoclonal antibody shot approved to protect infants from RSV-related illness, raise questions about mass infant vaccination with the drug, according to a new preprint study.
The study by French scientist Hélène Banoun, Ph.D., which analyzed outcomes from the 2023-2024 respiratory syncytial virus (RSV) immunization campaign in the U.S., France, Spain and Luxembourg, contradicts some claims of success by U.S. public health agencies and medical associations.